These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 31425442)
21. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Fleeman N; Dundar Y; Dickson R; Jorgensen A; Pushpakom S; McLeod C; Pirmohamed M; Walley T Pharmacogenomics J; 2011 Feb; 11(1):1-14. PubMed ID: 20877299 [TBL] [Abstract][Full Text] [Related]
22. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. Sychev DA; Zastrozhin MS; Miroshnichenko II; Baymeeva NV; Smirnov VV; Grishina EA; Ryzhikova KA; Mirzaev KB; Markov DD; Skryabin VY; Snalina NE; Nosikova PG; Savchenko LM; Bryun EA Drug Metab Pers Ther; 2017 Sep; 32(3):129-136. PubMed ID: 28787271 [TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis. Yin A; Shang D; Wen Y; Li L; Zhou T; Lu W Eur J Clin Pharmacol; 2016 Aug; 72(8):933-44. PubMed ID: 27117554 [TBL] [Abstract][Full Text] [Related]
25. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. Skogh E; Sjödin I; Josefsson M; Dahl ML J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135 [TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient. Paulzen M; Tauber SC; Kirner-Veselinovic A; Gründer G J Clin Psychiatry; 2011 Nov; 72(11):1465-7. PubMed ID: 22127193 [No Abstract] [Full Text] [Related]
27. Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Bachmann CJ; Haberhausen M; Heinzel-Gutenbrunner M; Remschmidt H; Theisen FM Ther Drug Monit; 2008 Feb; 30(1):108-12. PubMed ID: 18223472 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia. Sun L; McDonnell D; von Moltke L Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514 [TBL] [Abstract][Full Text] [Related]
29. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Sjöqvist F; Eliasson E Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719 [TBL] [Abstract][Full Text] [Related]
30. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417 [TBL] [Abstract][Full Text] [Related]
31. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636 [TBL] [Abstract][Full Text] [Related]
32. Use of very-high-dose olanzapine in treatment-resistant schizophrenia. Batail JM; Langrée B; Robert G; Bleher S; Verdier MC; Bellissant E; Millet B; Drapier D Schizophr Res; 2014 Nov; 159(2-3):411-4. PubMed ID: 25278103 [TBL] [Abstract][Full Text] [Related]
33. Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia. An H; Fan H; Chen S; Qi S; Ma B; Shi J; Wang Z; Yang F J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):255-259. PubMed ID: 33814547 [TBL] [Abstract][Full Text] [Related]
34. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795 [TBL] [Abstract][Full Text] [Related]
35. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603 [TBL] [Abstract][Full Text] [Related]
36. Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. Vanwong N; Ngamsamut N; Medhasi S; Puangpetch A; Chamnanphon M; Tan-Kam T; Hongkaew Y; Limsila P; Sukasem C J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):185-191. PubMed ID: 26780783 [TBL] [Abstract][Full Text] [Related]
37. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Cabaleiro T; López-Rodríguez R; Ochoa D; Román M; Novalbos J; Abad-Santos F Hum Psychopharmacol; 2013 May; 28(3):205-14. PubMed ID: 23559402 [TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment. van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540 [TBL] [Abstract][Full Text] [Related]
39. Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia. Tajiri M; Suzuki Y; Sugai T; Tsuneyama N; Someya T PLoS One; 2018; 13(7):e0199922. PubMed ID: 30016331 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. Dittmann RW; Meyer E; Freisleder FJ; Remschmidt H; Mehler-Wex C; Junghanss J; Hagenah U; Schulte-Markwort M; Poustka F; Schmidt MH; Schulz E; Mästele A; Wehmeier PM J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):54-69. PubMed ID: 18294089 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]